导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.62% | 1364/4763 |
| 近一周 | -1.31% | 1995/5452 |
| 近一月 | -5.90% | 3931/5409 |
| 近一季 | -14.21% | 4250/5219 |
| 近半年 | -3.08% | 2378/4908 |
| 近一年 | 6.37% | 1598/4388 |
| 近两年 | 92.73% | 694/2951 |
| 近三年 | 52.33% | 525/2250 |
| 成立以来 | 132.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.59% 883/4961 |
22.99% 1113/5312 |
- - |
- - |
| 2025 | 44.14% 638/4813 |
5.13% 821/3635 |
6.02% 503/4076 |
30.49% 1176/4524 |
-0.90% 2700/4813 |
| 2024 | 3.99% 1899/3463 |
-7.67% 2181/2808 |
-2.57% 1206/3014 |
15.59% 1677/3129 |
0.01% 1286/3463 |
| 2023 | -8.97% 1077/2656 |
5.52% 779/2280 |
-0.68% 402/2385 |
-9.86% 1905/2515 |
-3.63% 746/2655 |
| 2022 | -27.63% 1496/2207 |
-18.79% 1396/1919 |
6.43% 700/2016 |
-14.27% 1059/2113 |
-2.34% 1798/2208 |
| 2021 | 21.76% 160/1822 |
-5.37% 919/1255 |
25.39% 88/1330 |
-3.15% 616/1466 |
5.95% 252/1822 |
| 2020 | 59.60% 127/1250 |
2.54% 133/1028 |
30.12% 64/1067 |
8.41% 713/1164 |
10.33% 599/1184 |
| 2019 | 44.60% 167/1092 |
29.46% 273/754 |
-6.58% 512/804 |
9.59% 54/850 |
9.10% 262/918 |
| 2018 | - - |
- - |
- - |
- - |
-9.34% 142/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 海富通创业板增强A VS. 长安沪深300非周期A(740101) |